Cat Allergy in Humans Market

Market Synopsis:

The Global Cat Allergy in Humans Market was valued at USD 3.17 Billion in 2022 and is expected to reach a value of USD 4.94 Billion by 2030. The Global Market is anticipated to grow to exhibit a Compound Annual Growth Rate (CAGR) of 5.70% over the forecast period.

Cats are popular pets and a common source of allergies. Humans are allergic to cat allergens, typically known as glycoproteins in cat saliva. Fel d 1 (secreted by the sebaceous gland) and Fel d 4 are the two glycoprotein allergens that cats produce most frequently (secreted from cat saliva). Watering eyes, sneezing, chapped lips, wheezing, chest constriction, nasal congestion, and itching are among the most typical signs of an allergic reaction to cats. According to the National Institutes of Health, those who have chronic respiratory conditions like asthma, COPD, or CFTR are most susceptible to acquiring a cat allergy. Skin-prick testing, blood tests, and a patient's medical history can all be used to diagnose cat allergies. Antihistamines and decongestants are among the available treatments for cat allergies. In addition, synthetic epitope vaccines are occasionally regarded as the best option for long-term relief from cat allergy symptoms.

Those with chronic respiratory conditions are more susceptible to acquiring a cat allergy. As a result, the global market for treating cat allergies is expanding significantly along with the increase in patients suffering from chronic respiratory diseases. Emphysema (COPD) and asthma are two examples of significant conditions that are thought to substantially increase the risk of cat allergy in the general population. In addition, cat owners are developing pet allergies as cats become more and more popular as pets. In the U.S. and Europe, for instance, allergies to cats are prevalent; according to skin prick tests, 17% of Americans and 8% of European Union citizens are allergic to cats, respectively. Additionally, some families are more prone than others to allergic reactions. As a result, allergic illnesses are more common in children born into these families.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Competitive benchmarking
• Historical data & forecasts
• Company revenue shares
• Regional opportunities
• Latest trends & dynamics
• Power BI Report (Dashboard)

Speak To Analyst

Market Segmentation:

The Cat Allergy in Humans Market is segmented on the basis of treatment, application, and distribution channel. First, the market is segmented on treatment: Antihistamines, Corticosteroid Nasal Sprays, Decongestants, Leukotriene Inhibitors, and Others. Based on application, the market is segmented into Allergy Treatment and Allergy Prevention. Finally, based on distribution channels, the market is segmented as Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Based on Treatment:

The market is sub-segmented on basis of Treatment: Antihistamines, Corticosteroid Nasal Sprays, Decongestants, Leukotriene Inhibitors, and Other Treatments. By 2031, the Antihistamines market sub-sector is anticipated to rule in terms of therapy. In cases of pet allergies, Antihistamines are the first line of defense. They are affordable, widely accessible, and offer quick relief. Antihistamines relieve allergy symptoms like itchy, watery eyes, nasal congestion, runny nose, sneezing, or nasal channel enlargement. They also treat hives and other skin rashes. The patient may feel better during the day and sleep better at night by treating these symptoms. The severity of the allergy symptoms dictates the antihistamine dosage.

Based on Application:

The market is divided into two sub-categories based on Application: Allergy Treatment and Allergy Prevention. The Allergy Treatment sub-segment dominated the global landscape in 2021. During the projection period, the sub-segment is anticipated to be driven by Anti-Allergy medications' low price and easy availability. In addition, the increase in Allergic Rhinitis Prevalence and the expansion of government-funded healthcare initiatives to increase public knowledge of cat litter allergy in humans are contributing factors to the segment's growth. On the other hand, the market for allergy therapy is being driven by rising global pollution levels and distinct genetic alterations. Additionally, the industry is anticipated to grow over the following years as more people turn to immunotherapy to treat pet allergy issues due to the therapy's high level of efficacy.

North America is projected to Grow at the Highest CAGR During the Forecast Period

This growth can be attributed to rising pet ownership knowledge and cats' extensive presence worldwide. Technological breakthroughs also drive the demand for allergy medications that mainly target cat allergens. In terms of revenue share in 2021, North America is anticipated to contribute the most. Increased public knowledge of cat allergies, a rise in the number of veterinarians, and rising disposable income levels are the main drivers of this regional market. About 15% of Americans experience cat allergies each year, according to the American Academy of Allergy, Asthma, and Immunology. In addition, due to the presence of significant market participants, the United States dominates in North America.

Competitive Landscape:

The key players in the Global Cat Allergy in Humans Market include- Bayer AG, Covis Pharma B.V, HollisterStier Allergy (Jubilant Pharma), Cipla Limited, GlaxoSmithKline plc, Merck & Co. Inc, Regeneron Pharmaceuticals Inc, Saiba Animal Health AG, Sanofi, Stallergenes Greer., Other prominent players, and others.

Segmentation of the Global Cat Allergy in Humans Market: